Previous 10 | Next 10 |
TEL AVIV, Israel , Jan. 8, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that management will provide a corporate update at the 2020 Biotech Showcase in San Francisco, California . 202...
The following slide deck was published by BioLineRx Ltd. in conjunction with this Read more ...
Sarepta Therapeutics (NASDAQ: SRPT ) +31% on FDA nod for golodirsen. More news on: Sarepta Therapeutics, Inc., BioLineRx Ltd., The Royal Bank of Scotland Group plc, Stocks on the move, Read more ...
BioLineRx (NASDAQ: BLRX ) is up 21% premarket on the heels of updated data from the triple combination arm of the ongoing Phase 2a COMBAT/KEYNOTE-202 study. More news on: BioLineRx Ltd., Healthcare stocks news, Stocks on the move, Read more ...
TEL AVIV , Israel , Dec. 13, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today updated data from the triple combination arm of the ongoing Phase 2a COMBAT/KEYNOTE-202 study. The data ...
Noteworthy events during the week of December 8 - 14 for healthcare investors. More news on: Roche Holding AG, Athenex, Inc., Anixa Biosciences, Inc., Healthcare stocks news, , Read more ...
Gainers: Aurinia Pharmaceuticals (NASDAQ: AUPH ) +95% . More news on: Aurinia Pharmaceuticals Inc., Duluth Holdings Inc., Atreca, Inc., Stocks on the move, Read more ...
Preliminary data from a Phase 2a clinical trial, COMBAT/KEYNOTE-202 , evaluating BioLineRx's (NASDAQ: BLRX ) lead oncology candidate BL-8040, combined with Merck's Keytruda and chemo, in metastatic pancreatic cancer patients showed a positive effect (these patients are highly treatment-r...
TEL AVIV , Israel , Dec. 5, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today preliminary data from the triple combination arm of the ongoing Phase 2a COMBAT/KEYNOTE-202 study showing...
TEL AVIV, Israel , Nov. 26, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will host an investor breakfast meeting on Thursday, December 5, 2019 at the Convene Conferen...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...